Clinical trials: Cytarabine
Leukemia, Nonlymphocytic, Acute
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years
AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.
- Trial name
- NCT00180102
- Testing
- Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone, early allogeneic PBSCT within induction therapy, autologous PBSCT
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia
Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
In relapsed or refractory AML allogeneic HCT is considered to be the only treatment by which long-term disease-free survival can be achieved.
- Trial name
- BRIDGE (NCT01295307)
- Testing
- Clofarabine
- Where
- 10 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Technische Universität Dresden
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer.
- Trial name
- NCT02587871
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- University of Southern California
Acute Lymphoblastic Leukemia
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
- Trial name
- NCT00774332
- Testing
- CODOX-M
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Cooperative Study Group A for Hematology
Myelodysplastic Syndromes
Nivolumab With Chemotherapy in Refractory MDS
There is evidence of involvement of checkpoint pathways, including PD-1, in the pathogenesis and resistance of myelodysplastic syndrome (MDS).
- Trial name
- NCT03259516
- Testing
- Nivolumab, Azacitidine, Fludarabine
- Where
- Russia
- Volunteers
- 2 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Melanoma
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. Two question are aimed to be answered by this study: 1.
- Trial name
- ChemoSensMM (NCT00779714)
- Testing
- DTIC (dacarbazine), paclitaxel + cisplatin, treosulfan + cytarabine
- Where
- 23 sites in Germany
- Volunteers
- 360 people
- Sponsor
- University of Wuerzburg
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Lymphoblastic Leukemia
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01366898
- Testing
- Dexamethasona, Idarubicine, ARA-C, Methotrexate
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.
- Trial name
- AMLCG 2008 (NCT01382147)
- Testing
- Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
- Where
- 32 sites in Germany
- Volunteers
- 396 people
- Sponsor
- Prof. Dr. Wolfgang Hiddemann
Leukemia
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells.
- Trial name
- NCT00002609
- Testing
- lintuzumab, cytarabine, idarubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
- Trial name
- HD-R3i (NCT01453504)
- Testing
- DHAP, Everolimus
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- University of Cologne
AML
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose…
- Trial name
- NCT03031249
- Testing
- Cytarabine, all-trans retinoic acid, Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoid Leukemia
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence.
- Trial name
- ReCALL (NCT05827549)
- Testing
- Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks)
- Where
- 10 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Ho Joon Im
Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with zanubrutinib for newly-diagnosed Mantle…
- Trial name
- NCT04624958
- Testing
- Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib Maintenance
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Leukemia, Promyelocytic, Acute
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)
The first purpose of this randomized trial will be to compare the best treatment group of APL 93 trial (ATRA with early introduction of anthracycline-AraC chemotherapy, followed by 2 consolidation anthracycline-AraC courses and…
- Trial name
- NCT00591526
- Testing
- Arac
- Volunteers
- 250 people
- Sponsor
- Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Mantle Cell Lymphoma
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with…
- Trial name
- BDH-MCL01 (NCT02858804)
- Testing
- Etoposide, Doxorubicin, Dexamethasone
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia With FLT3/ITD Mutation
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy.
- Trial name
- NCT05024552
- Testing
- Gilteritinib, Vyxeos
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
- Trial name
- NCT07106749
- Testing
- CD180 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia, AML
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and…
- Trial name
- NCT02287233
- Testing
- Venetoclax, Cytarabine
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 94 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.